Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced on November 6, 2025 that its Compensation Committee granted restricted stock unit awards covering 6,876 shares to six new non-executive employees under the 2024 Inducement Plan.

The awards were granted on November 3, 2025 as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date. The 2024 Inducement Plan is used exclusively for equity awards to individuals who were not previously employees or who return after a bona fide non-employment period.

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on November 3, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 6,876 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What did Praxis (PRAX) announce on November 6, 2025 about inducement awards?

Praxis announced RSU grants of 6,876 shares to six new non-executive employees under the 2024 Inducement Plan, granted November 3, 2025.

How do the Praxis PRAX restricted stock units vest and when do they vest?

The restricted stock units vest in four equal annual installments, subject to each employee's continued employment on each vesting date.

What is Nasdaq Listing Rule 5635(c)(4) in the Praxis PRAX grant context?

Under Nasdaq Rule 5635(c)(4), Praxis used an inducement plan to grant equity awards material to new hires who were not previously employees or who returned after bona fide non-employment.

How many employees received inducement RSU awards from Praxis (PRAX)?

Six new non-executive employees received the restricted stock unit awards.

Does the Praxis PRAX announcement state any immediate cash or earnings impact?

No; the announcement only describes equity awards and vesting terms and does not report cash expenses or earnings figures.